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Background: Pompe’s disease is a progressive myopathy caused by mutations in the lysosomal enzyme acid
alphaglucosidase gene (GAA). A wide clinical variability occurs also in patients sharing the same GAA mutations,
even within the same family.
Methods: For a large series of GSDII patients we collected some clinical data as age of onset of the disease,
presence or absence of muscular pain, Walton score, 6-Minute Walking Test, Vital Capacity, and Creatine Kinase.
DNA was extracted and tested for GAA mutations and some genetic polymorphisms able to influence muscle
properties (ACE, ACTN3, AGT and PPARα genes).
We compared the polymorphisms analyzed in groups of patients with Pompe disease clustered for their
homogeneous genotype.
Results: We have been able to identify four subgroups of patients completely homogeneous for their genotype,
and two groups homogeneous as far as the second mutation is defined “very severe” or “potentially less severe”.
When disease free life was studied we observed a high significant difference between groups. The DD genotype in
the ACE gene and the XX genotype in the ACTN3 gene were significantly associated to an earlier age of onset of
the disease. The ACE DD genotype was also associated to the presence of muscle pain.
Conclusions: We demonstrate that ACE and ACTN3 polymorphisms are genetic factors able to modulate the
clinical phenotype of patients affected with Pompe disease.
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Glycogen Storage Disease type II (GSDII) or Pompe dis-
ease (OMIM 232300) is a lysosomal storage disorder
caused by mutations in the acid alpha-glucosidase (GAA)
gene whose frequency is about 1 in 40000–50000 in
European and US Populations and apparently much lower
in Australia or Portugal [1]. A comprehensive review of
clinical and genetic data was published by van der Ploeg
and Reuser [2]. More than 300 different mutations have
been described [3], without strict genotype-phenotype
correlations [4]. Even within families large variations in* Correspondence: paola.defilippi@unipv.it
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unless otherwise stated.disease severity can be observed; a recent report by Wens
et al. [5] demonstrates as presenting symptoms were dif-
ferent in sibling in 8/22 (36%) families. The clinical het-
erogeneity of GSDII is more frequently observed among
late-onset patients (i.e. childhood, juvenile and adult onset)
than among early-onset cases [6], it is observed even within
families [6,7] and is reported also in animal models [8].
The same mutation can be observed in both infantile
and late onset patients even if with different incidence;
for instance, in two different groups of Italian patients,
the c.525delT was observed in 13,8% in cases with the
infantile form [9] but also in 3,8% of cases of late onset
disease [10]. Conversely the same authors reported an
incidence of 3,4% for the c.2237G > A mutation in in-
fants as compared to an incidence of 10,3% in adults.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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which never occurs in patients with the classic infantile
form.
This mutation was first reported by Huie et al. [11]
and then demonstrated to be common in late onset pa-
tients by many groups as Montalvo et al. [12], Gort et al.
[13], Kroos et al. [14] and Joshi et al. [15]; it allows the
production of normally spliced GAA mRNA in a very
small amount, and the production of tree splicing vari-
ants [16,17]. The presence of even a limited amount of
normal mRNA has been interpreted as the cause of
delayed onset of the disease in patients carrying this
mutation [15].
However genotypes including the c.-32-13T > G plus
a second mutation still show a very variable clinical
presentation.
The extensive variability discussed prompted several au-
thors to suggest that other (genetic) factors may consist-
ently influence the clinical outcome of the disease [4,5].
The polymorphism of Angiotensin converting enzyme
(ACE) had been previously reported as genotype modu-
lator in McArdle disease, also a glycogen storage disease,
by Martinuzzi et al. 2003; they reported that the number
of D alelles was significantly correlated with severity of
phenotype.
Thus we decided to evaluate if also in Pompe’s disease
the different ACE polymorphism could modulate the
final phenotype of the disease. As ACE polymorphism is
relevant also in muscle fiber type composition and ath-
letic performances, we included in our study two more
genes whose polymorphisms may also act on the same
parameters, as alpha actinin 3 (ACTN3) and peroxisome
proliferative activated receptor alpha(PPARα); Angioten-
sinogen (AGT) was finally added as its protein is the
precursor of the substrate for ACE.
We then studied a large sample of late-onset GSDII
patients, all sharing the c.-32-13T > G mutation and di-
vided them in subgroups based on the second mutation.
Our aim was to elucidate whether groups of cases
homogeneous for the presence of the same couple of
GAA mutations but differing in some genetic polymor-
phisms may show distinct clinical features as for: age of
onset, muscle pain, muscle and respiratory dysfunction,
serum creatine kinase (CK).
Methods
Patients and clinical methods
Thanks to the collaboration with the GSDII - Italian
Group, we recruited a large series of GSDII patients (n =
126, 58 males; age range 10–83) as described in Angelini
et al. [18].
The patients were diagnosed in many different centres
and no evidence that index cases sharing the same mu-
tations were related was recorded.Informed consents were obtained according to the
rules of the centres caring for the patients, who also pro-
vided clinical data. All the work was carried on in com-
pliance with the Helsinki Declaration.
We collected the following data: age of onset of the dis-
ease (defined as the age the patient first notices difficulties
in running/climbing stairs), thus disease free survival is
the time from birth to the age of symptom onset; presence
or absence of muscular pain at any time after the diagno-
sis; Walton score [19]; 6-Minute Walking Test (6MWT)
[20]; Vital Capacity, as expressed as percentage of de-
crease compared to controls (VC%); creatine kinase (CK).
Walton score, 6MWT, and VC were the latest available
data for patients not on ERT and the latest estimation
prior to starting ERT for the others. As for CK, we re-
ported the levels measured at the time of diagnosis; due
to inhomogeneous reference values across laboratories,
we calculated a ratio by dividing each patient’s CK by
the upper limit of normal range of that site’s local la-
boratory. Physicians who collected clinical data were
blind to genetic data.
Molecular analysis
Among all patients in whom both mutations were iden-
tified in our three labs (C.D, C.A. and M.M.), we selected
85 cases carrying the c.-32-13T > G on one allele.
The definition of “very severe (VS)” or “potentially less
severe (PLS)” is as in http://www.pompecenter.nl; the se-
verity rating of mutations is according to [21] based on
size, amount and enzymatic activity of mutated protein
expressed in transfected COS-7 cells.
The genetic polymorphisms were analysed by P. De F.
and K.S.
DNA was extracted by routine methods using the
“GENE ELUTE” kit by Sigma, amplification of all GAA
exons was performed according to published methods [22].
Polymorphisms analyzed
1) The angiotensin converting enzyme (ACE)
polymorphism is characterized by the presence
(insertion (I)) or absence (deletion (D)) of a 287-
base-pair alu repeat within intron 16 [23].
2) The R577X polymorphism in alpha-actin-3 (ACTN3) is
a C to T transversion at position 1,747 in exon 16 [24].
3) The Peroxisome proliferator-activated receptor alpha
(PPARα) polymorphism is located in intron 7 (456 bp
upstream of exon 8) and is a G to C substitution [25].
4) The polymorphism of the angiotensinogen (AGT)
gene is a T to C transition at base 704 resulting in
Met235Thr [26].
The methods for polymorphism analysis were reported
by Lindpainter et al. [23] (ACE), North et al. [24]
Table 1 Frequency of the different mutations observed in
our sample
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[26] (AGT).Mutations Allele 1 Allele 2 N° of pts. %
c.-32-13T > G (N = 85) c.525delT 21 24,7
c.2237G > A 13 15,3
Delexon18* 7 5,8
c.1927G > A 5 5,8
Very severe (VS) 13 17,6
Potentially less severe (PLS) 26 30,5
*Delexon18 is also referred in the literature as c.2481 + 102_2646 + 31del.Statistical methods
The independence of categorical variables was tested by
the X2 test. The comparisons of scores among groups
were made by the Kruskal-Wallis test.
The disease free survival of the different Allele 2
groups was compared by the logrank test when the pro-
portional hazard assumption was granted. The survival
curves shown are estimated by the Kaplan-Maier (K-M),
or the K-M like method when the application of a Cox
model was possible.
The disease free life of the polymorphisms as well as
of their interaction was analyzed by lognormal paramet-
ric accelerated life survival models, which optimally fit-
ted the data.Structural modelling
A model of GAA was built with the M4T server v. 3.0
(Bioinformatics. (2007) 23, 2558–65; Nucleic Acids Res.
(2007) 35, W363-68; J. Struct. Funct. Genomics. (2009)
10,95-9). The submitted sequence included the full-
length GAA sequence (UNIPROT number P10253, resi-
dues 1–952). Templates used were chain As of human
maltase-glucoamylase (2QLY and 3L4T). Dope score
(Shen MY, Sali A. “Statistical potential for assessment
and prediction of protein structures” Protein Sci. 2006
Nov;15(11):2507–24) was −108411 and PROSA 2003
ZSCORE was −13.08 (Sippl,M.J. “Recognition of Errors
in Three-Dimensional Structures of Protein, Proteins,
17: 355–362 (1993)). Images were generated with Pymol
(The PyMOL Molecular Graphics System, Version 1.5.0.4
Schrödinger, LLC).Results
We collected a large series of patients with non classic
forms of Pompe disease, all carrying the c.-32-13T > G
mutation, a mutation which is common in these forms
of the disease. As to the second mutation, we have been
able to identify four subgroups of patients completely
homogeneous for their genotype, in details their genotypes
were: c.-32-13T >G/c.525delT; c.-32-13T >G/c.2237G >
A; c.-32-13T >G/Delexon18; c.-32-13T >G/c.1927G >A.
Finally two groups were defined “homogeneous” as far as
the second mutation is defined “very severe” or “poten-
tially less severe” according to the database http://www.
pompecenter.nl (Table 1). In addition 21 mutations other
than those reported in Table 1, were observed in more
than one patient, but the small size of this subgroups pre-
vented further correlation with clinical features; these mu-
tations are listed in Additional file 1: Table S1.Correlation between GAA genotypes and clinical
parameters
Disease-free life
We collected the information on the age of onset of the
disease (and thus on the disease free life) in all 85
patients.
We compared the disease-free survival between five
genotypes all of them showing the c.-32-13T > G as first
allele and carrying a different mutation on the second al-
lele (c.-32-13T > G/c.525delT; c.-32-13T > G/c.2237G >
A; c.-32-13T > G/Delexon18; c.-32-13T > G/c.1927G > A;
c.-32-13T > G/VS and c.-32-13T > G/PLS as described in
Table 1), and a significant difference was observed: p =
0.031. We also compared the genotypes in which the c.-
32-13T > G was associated to a mutation classified as
“very severe” (VS) with those in which IVS1 was associ-
ated to a mutation classified as “potentially less severe”
(PLS) and no significant difference was found between
the two groups (P = 0.231) (data not shown).
The c.525delT group was excluded from the compari-
son because it does not satisfy the proportional hazard
assumption (see statistical methods).
Figure 1 shows the estimated disease-free survival for
the c.525delT group, the c.1927G > A group and the
whole of the other groups; the c.-32-13T > G/c.1927G >
A group shows a shorter disease-free survival compared
to the other groups (p = 0.000163).
The c.1927G > A mutation is a missense mutation,
resulting in the p.Gly643Arg and as the genotype c.-32-
13T > G/c.1927G > A behaves differently, we analyzed
where the substituded aminoacid, Arginin, is placed in
the structure of the molecule (Figure 2).
Other clinical features studied were similar through
different GAA genotypes, as reported in Table 2.
Correlation between ACE, ACTN3, AGT and PPARα
polymorphisms and clinical parameters
As the polymorphisms in the genes studied (ACE,
ACTN3, AGT and PPARα) are relevant for some muscu-
lar physiological and structural functions, we analyzed
whether a correlation with some clinical parameters
could be observed.
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Figure 1 Comparison of disease-free life among patients with genotypes c.-32-13T > G/c.525delT (n = 21), c.-32-13T > G/c.1927G > A
(n = 5), c.-32-13T > G/other (c.2237G > A, Delexon18, VS, PLS) (n = 59). The curve for c.-32-13T > G/c.525delT is a Kaplan-Mayer estimate, the
other two are pseudo K-M estimates derived from a Cox model.
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our sample did not differ from that reported in controls
(ACE [23], ACTN3 [27], AGT [26], and PPARα [28]) see
Table 3.
No difference was found for age, gender and disease
duration for any of the different subgroups identified by
the polymorphisms studied for any gene (data not
shown); we report only details about ACE and ACTN3
as they are the only genes whose polymorphisms showed
some significant differences (see below). Analysis for
age, gender and disease duration in patients with DD/
ID/II genotype for ACE gave respectively the following p
values (Kruskal-Wallis): 0.31; 0.41 and 0.76. Analysis forFigure 2 Left: structural model of GAA. Right: magnification of the catal
(c.1927G > A).age, gender and disease duration in patients with XX/
RX/RR genotype for ACTN3 gave respectively the fol-
lowing p values (Kruskal-Wallis): 0.59; 0.44 and 0.78.
A shorter disease-free life was found, depending on
the number of D alleles in the ACE genotype (p = 0.003,
n = 85), as well as the number of X alleles in the ACTN3
genotype (p = 0.024, n = 85) (Figure 3, a, b), while no sig-
nificant association was found with AGT and PPARα
polymorphisms (data not shown).
The interaction between ACE and ACTN3 genotypes
was non-significant in the accelerated lognormal model
(p = 0.85); however, the numbers of D and X alleles were
significantly associated to an earlier age of onset ifytic site. Grey sticks: catalytic residues. Grey spheres: G643R mutation
Table 2 Summary of clinical and biochemical data assessed in the different Allele 2 groups, and statistical analysis (p)
Allele 2 Presence of pain,
% [68]
Walton score 6 MWT VC % CK
Median, (IQR), [77] Median, (IQR), [43] Median, (IQR), [43] Median, (IQR), [40]
c.525delT 38.9 [7/18] 2.25 (2 – 3.1) [20] 313 (196–386 ) [9] 61.0 (49.0 - 71.0) [9] 3.3 (2.3 - 4.0) [8]
c.2237G > A 33.3 [ 3/9] 2.25 (1.2 -4.5) [10] 144 (65–244) [4] 87.5 (59.7 - 89.0) [6] 1.35 (0.7 - 3.1) [6]
Delexon18 20.0 [1/5] 1.0 (3–0) [5 ] 378 (194–432) [5] 67.0 (56.0 -78.0) [5] 0.8 (0.8 - 1.5) [5]
c.1927 G > A 20.0 [1/5] 3.0 (2–0) [5 ] 307 (199–333) [3] 57.5 (47.7- 65.5) [4] 3.0 (1.9 - 6.3) [3]
VS 33.3 [4/12] 3.0 (4–0) [13] 292 (208–375) [2] 43.5 (32.7 - 54.2) [2] 2.8 (1.7 - 3.8) [2]
PLS 52.6 [10/19] 3.0 (4–0) [24] 368 (256–394) [12] 68.1 (63.0 - 79.3) [17] 1.8 (1.5 - 3.0) [16]
p 0,655 0,7021 0.493 0.461 0.170
In brackets [ ] the number of cases for which the data are available. IQR: interquartile range.
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allele and p = 0.032 for the X allele).
Table 4 shows the p values obtained when analyzing the
median of the different clinical data (Walton score, 6MWT,
CK and VC) in relation to the different polymorphisms.
Concerning the presence of pain, the DD genotype of
ACE was the most represented genotype among patients
reporting pain (DD = 69,2%; ID = 23,8%; II = 40,0%), and
there is significant difference from the genotype distribu-
tion in the whole group of patients (p = 0,028; n = 68).
There is no significant association between any ACTN3
genotype and pain (p = 0,42). It is noteworthy that -
among the 68 patients with available data about pres-
ence/absence of pain - the four cases with the DD/XX
genotype consistently reported pain, while the four pa-
tients with the II/RR genotype did not (p = 0,029).
We did not attempt to analyze the combined ACE-
ACTN3 genotypes in relation to other clinical parame-
ters, since the number of cases for each single genotype
was too small; similarly, we did not test any other associ-
ation of polymorphisms from the different genes, as the
association of single genes with clinical parameters was
non-significant (see Table 4).
Discussion
Pompe disease is a monogenic autosomal recessive dis-
order caused by mutations in the acid alpha glucosidase
gene (GAA, OMIM 606800), which is the only gene as-
sociated to the phenotype.Table 3 Distribution of the different polymorphisms in
our sample as compared to data reported in controls
ACE ACTN3 AGT PPARα
DD ID II RR RX XX TT TC CC GG GC CC
Patients 23 46 15 25 44 15 23 33 17 43 32 5
Controls 29 37 14 35 78 41 41 59 19 322 161 5
Number of cases: 85 84 74 80
Patients controls 80 154 119 500
Xsquare test, p P = 0,448 p = 0.238 p = 0.474 p = 0.136
Hypothesis tested: cases and controls have the same distribution.Genotype-phenotype correlations have been widely
discussed, and a recent paper by Kroos et al. [4] under-
lines the main information available. They report that
genotype-phenotype correlation is strict, meaning that
biallelic mutations able to completely abolish protein
function cause the classic infantile Pompe disease, while
the presence of at least one mutation allowing the pro-
duction of a protein with some residual activity causes
the late-onset forms. However, the well documented
clinical variability in groups of patients with similar ge-
notypes [14] still makes genotype-phenotype correlation
an unresolved issue; modifying genetic factors are ex-
pected to influence the final clinical presentation of the
disease [4].
Enzyme Replacement Therapy (ERT) is available since
2006 and data as to the variable treatment outcome
among different patients have been reported [29,30], but
not related to the GAA genotypes.
A role for modifiers genes has been reported for sev-
eral diseases as Cystic Fibrosis [31], including a glycogen
storage disorder, i.e. McArdle disease [32,33], and De
Filippi et al. reported some data on the effect of the ACE
I/D polymorphism on phenotype in 38 Pompe adult pa-
tients [34].
Mutations
As recently reported by Remiche et al. [35] patients het-
erozygous for the c.-32-13T > G and carrying different
types of severe mutations on the second allele showed a
more severe phenotype.
In our study when comparing groups of patients with
the same GAA genotypes (see results and Table 1 for de-
tails) for disease-free life (Figure 1) we observed a highly
significant difference (p = 0.000163) for the c.-32-13T >
G/c.1927G > A genotype, which showed an earlier age of
onset, at any age, compared to other genotypes. This
mutation occurs in both infantile and adult patients [36];
is reported to be associated with 1-2% of residual en-
zymatic activity, and with impairment in protein matur-
ation [37]; as a barely detectable amount of the 76 kDa
active protein is produced, is classified as ‘potentially less
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Figure 3 Disease-free life according to ACE and ACTN3 polymorphisms. a) The number of D alleles of ACE is significantly associated to a
shorter disease-free life. b) The number of X alleles of ACTN3 is significantly associated to a shorter disease-free life.
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Table 4 p values observed when comparing clinical and
laboratory data and the polymorphisms studied
Polymorphism Walton§ Pain* 6MWT§ CK§ VC%§
ACE I/D 0,95 0,028 0,33 0,218 0,35
ACTN3 R577X 0,62 0,42 0,37 0,88 0,46
PPARα intron 7 0,19 0,55 0,33 0,50 0,14
AGT Met235Thr 0,63 0,07 0,98 0,63 0,31
§kruskall wallis test *fisher test.
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lysis of c.1927G > A (p.G643R) mutation demonstrates
that it could affect the catalytic site of the protein (see
Figure 2). Though homology modelling would suggest a
conservation of the protein general shape, SCpred [38]
predicts G643 to be a stabilization centre, which suggests
that impaired maturation could be a possible cause of re-
duced expression in agreement with biochemical data.
Some data about modelling for mutations other than
p.G643R were reported by Sugawara et al. in [39].
Other mutations show impaired maturation with se-
vere reduction of catalytic activity, so that overall these
data alone do not explain why the c.-32-13T > G/
c.1927G > A genotype is related to a significantly shorter
disease-free life. Remiche et al. [35] also observed a
more severe clinical presentation in their patients with
the same genotype “despite the less severe qualification
of this mutation”. A possible explanation is given by the
study of ACE polymorphism (see below).
The c.-32-13T > G/c.525delT genotype shows in our
group of patients a particular behaviour by concentrat-
ing onsets in the young-adult age interval (15 – 45
years), contrary to the other groups in which the onset
of clinical symptoms may be at older ages as well. This
mutation does not allow the production of any protein
[40] and this biochemical information fits with the ab-
sence of very late disease onset, even in association with
the mild c.-32-13T > G on the second allele. Again many
other CRIM negative mutations are known, and the bio-
chemical data alone do not explain the different behav-
iour of this mutation.
To better understand why a specific missense muta-
tion as c.1927G > A, allowing the production of a small
amount of protein or a non sense mutation as c.525delT
CRIM negative both result in a earlier presentation of
the disease, further studies as GAA activity in single
cells, or analysis of binding of splicing factors or the
study of production of the different isoform in muscle
biopsies or in cultured muscle cells can be envisaged.
The lack of differences between VS and PLS is not sur-
prising, as the residual activities of the two groups, ex-
tensively overlaps [3].
Other clinical parameters tested in relation to the differ-
ent mutations failed to demonstrate significant differences.We are aware that these features represent, actually, “dy-
namic” parameters, whose values may change during the
course of the disease.
Available information show that there are differences
in GAA expression in different tissues [41], and that the
pathogenesis of the disease is far more complex than
previously thought [42]; moreover, GAA is a target for
the Notch-1 signalling pathway [43] and interacts with
NUMBL (http://thebiogrid.org/108823/summary/homo-
sapiens/gaa.html); both Notch-1 and NUMBL genes are
involved in the regulation of myogenesis [44,45].
The structural details of these interactions are not
known, so the hypothesis that different mutations, even if
primarily always causing glycogen storage, may have rele-
vance for other cell functions and in turn for the final clin-
ical phenotype, can be investigated in the future.
Polymorphisms
Based on the differences in histopathological changes in
distinct GAA knockout mice, Ponce et al. already in 1999
suggested that differences in their genetic background
may play a role as a phenotype modifier and the existence
of modifier genes was discussed by Kroos et al. [4].
Following previous work [32–34], we selected the
polymorphisms under study (ACE, ACTN3, PPARα, and
AGT) because of the known relevance of their genes in
muscle structure to verify if any of them could act as
modifier gene.
As expected (Table 3) the distribution of their geno-
types did not differ from controls.
ACE
The association between the DD genotype of ACE and
an earlier age of onset (Figure 3a) is statistically signifi-
cant and confirms our previous observation [34].
ACE was chosen as a candidate modifier gene since
the well-known I/D polymorphism has been demon-
strated to influence several muscle features such as fiber
type composition [46], muscle properties [47] and sport
performances [48]. ACE polymorphism also modulates
the clinical presentation of McArdle disease (the D/-,
DD genotypes being associated to a more severe pheno-
type) [34,49]; based on these observations, a clinical trial
with ACE-inhibitors was started [50].
We defined the age of onset as the age at which pa-
tients experienced the first difficulties in climbing stairs/
running; we believe that this information can provide
data as to disease-free life and can be homogeneously
collected also by different centres. The association of a
shorter disease-free life with the DD genotype fits with
available data on ACE and I/D allele function: i) the DD
genotype is associated with a higher amount of circulat-
ing protein, which will cause increased levels of angio-
tensin II and result in vasoconstriction; our hypothesis is
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ability to working muscle would occur. ii) ACE may in-
fluence muscle metabolic efficiency, since an excess of
II genotype was observed in elite mountaineers, and
likely related to increase in type I/endurance muscle fi-
bres [51]. The unfavourable prognostic profile of pa-
tients with the DD genotype and thus with a relative
predominance of type 2 muscle fibres is in full agree-
ment with the observation by van den Berg el at [52],
that “among non-classic patients…those with early on-
set of symptoms tend to have more type 2 muscle
fibers”.
Overall these data fit with the idea that the DD geno-
type may result in muscles with reduced metabolic func-
tion, and that the addition of this genotype to the
background GAA mutations may favour an earlier clin-
ical evidence of muscle impairment. In fact it appears
relevant that three out of five of patients carrying the
c.1927G > A mutation for whom a shorter disease-free
life was demonstrated, (see Additional file 1: Table S1)
shared the DD ACE genotype, and their mean age of on-
set was 17,6 years, while the age of onset of the two
cases with ID and II were respectively 34 and 30.
The DD genotype was also associated with muscle
pain (p = 0,028); pain in Pompe disease was previously
reported [53] but, never addressed in detail as regards
its prevalence, features, pathogenesis, and treatment op-
tions. We used anamnestic records about presence or
absence of back/limbs spontaneous muscle pain (not in-
duced by cramps or exercise-induced fatigue), collected
by neurologists with high experience in caring patients
with Pompe disease. Some caution must be adopted in
considering this data, due to the subjective nature of this
feature, and since we did not use a detailed scale for the
evaluation of pain.
However, some report support a relation between pain
and presence of DD alleles: In fact the relevance of the
DD genotype in a microvascular disorder as diabetic ne-
phropathy was reported in mice by Huang et al. [54] and
was confirmed in a meta analysis of human data by Ng
et al. [55]. Microvessel damage and reduced clearance of
toxic metabolites (lactic acid?) from muscle damage
(caused by vasoconstriction related to the DD genotype)
is a working hypothesis for this feature.
A detailed study of the association of ACE and
ACTN3 polymorphisms with histochemical data ob-
tained from muscle biopsies, are included in a manu-
script in preparation.
ACTN3
Similar results were obtained also for the polymorphism
R577X in ACTN3 gene, and the XX genotype is signifi-
cantly (p = 0,024) associated with an early onset of the
disease in our sample (Figure 3b).The X allele is observed in 18% of the population and
it is associated to the lack of the encoded protein α-
actinin 3, which expression is restricted to fast muscle
(type 2) fibers. The high frequency of ACTN3 577X al-
lele in healthy controls demonstrates that the stop codon
is a non-pathogenic polymorphism.
The 577X allele has been associated with better endur-
ance performances [56], linked to type 1 (slow) fibres in
which α-actinin is not expressed. The XX genotype has
been reported to be connected with muscle damage after
extremes performances [57], to muscle function decline
with age [58], to a lower cross sectional area of thigh
muscle in elderly women, and to a restricted transform-
ation of the muscle fiber composition to type 2 fibers in
response to long-term muscle disuse [59].
Overall these data indicates that XX genotype will
result in impaired muscle function with age and re-
duced motility, and fits with our observation of short-
ening of disease free life in Pompe’s patients carrying
this genotype.
ACE + ACTN3
We then tested if the contemporary presence of the DD
(ACE) and XX (ACTN3) genotypes, if found in the same
patient, will again be associated with some of the clinical
features examined. In fact (see results) the DD/XX geno-
type is significantly associated to a shorter disease free
survival than any other combined genotypes. The two
genes have completely different functions as ACE is rele-
vant in renin angiotensin system and ACTN3 encodes a
muscle structural protein; these differences in function
are in agreement with the observation that there is no
statistical evidence for interaction between the two genes
but an additive effect is present. Similarly, in a small
group of patients, preliminary evidence for an additive
effect of the two genotypes was observed also for pain,
which was recorded in four out of four cases showing
the DD/XX genotype, while pain was not reported for
five cases with the II/RR genotype.
Based on these data, pain in Pompe’s patients could be
tentatively interpreted as the result of muscle “damage”
influenced by genetic factors (among them the polymor-
phisms studied) more than to the GAA genotype.
Other polymorphisms tested failed to demonstrate sig-
nificant association with Walton score, 6MWT, CV and
CK (see Table 4). The ACTN3 XX genotype was repor-
ted to be associated with a lower CK baseline levels in
healthy controls but as its contribution was only 3,5% of
variation [27], so it is not surprising that we did not find
a correlation for the very high CK levels in our group of
patients as increased in CK levels is mainly due to
muscle damage.
The observation that ACE and ACTN3 may modify
age of disease onset, but not severity, in our opinion can
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of different clinical details of such a complex trait.
Conclusions
Our data demonstrate that some clinical differences
among patients (as age of onset or presence of pain) can
be related to their genotypes when homogeneous groups
of cases are compared; we expect that the study of well
defined clinical features in large group of cases alike in
their genetic background, will enable us to establish fur-
ther genotype-phenotype correlations.
The results obtained by studying the polymorphisms
in several genes whose function is associated to muscle’s
behaviour show that only two of them, ACE and ACTN3,
was proven to be able to modify the clinical phenotype
of Pompe patients as regard to disease free life and pain.
The identification of two genes able to influence Pompe
phenotype clearly suggests that a large number of other
genetic polymorphisms, relevant for specific clinical de-
tails showing wide variation within family and among
patients, may be identified.
Our results demonstrate as the analysis of genotypic
variants other than those present in the disease causing
gene in patients with a well defined monogenic disorder,
are worthy to be tested to obtain new prognostic data,
and in the future larger series of polymorphisms can be
forecasted to be used in clinical practice for a better care
of patients also in relation to newly developed therapies.
Additional file
Additional file 1: Table S1. Details of the genotypes for GAA mutations
and ACE, ACTN3, PPARα and AGT polymorphisms far all subjects analyzed.
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